Cleavable vs Non-Cleavable Linkers: How to Choose for ADC Research

Choosing between cleavable and non-cleavable linkers is one of the key decisions in antibody-drug conjugate (ADC) development. The linker must keep the payload attached during circulation while allowing the intended drug-release process to occur after the ADC reaches the target cell. The right choice depends on more than linker stability. Researchers also need to consider intracellular trafficking, payload properties, conjugation chemistry, antibody characteristics, and the intended mechanism of action.

For ADC research, a cleavable linker is generally considered when controlled payload release is required through a specific chemical or enzymatic trigger. A non-cleavable linker is worth investigating when strong linker stability and lysosomal processing are central to the design. Neither approach is universally better. The most suitable option is the one that matches the biological pathway and the properties of the antibody-payload combination.

This guide explains how cleavable and non-cleavable ADC linkers work, compares their structural characteristics, and discusses how PEG-based spacers and functional groups can be considered during linker selection. It is intended for researchers evaluating ADC linker structures and bioconjugation materials.

What Is the Difference Between Cleavable and Non-Cleavable ADC Linkers?

The main difference is how the payload becomes available after an ADC enters a target cell. Cleavable linkers contain a bond or chemical structure designed to respond to a specific intracellular condition, such as low pH, reducing conditions, or lysosomal enzymes. Non-cleavable linkers do not rely on a separate cleavage trigger. Instead, the antibody component must undergo intracellular degradation before the payload-containing catabolite is generated.

In both designs, the linker connects the antibody and the cytotoxic payload. It must also maintain suitable stability during circulation and remain compatible with the selected conjugation strategy. A useful way to compare the two approaches is to look at the intended release pathway rather than simply labeling one linker as more stable than the other.

How Do Cleavable Linkers Release the Payload?

Cleavable ADC linkers are designed with a specific chemical or enzymatic trigger. After cellular uptake, the linker responds to conditions encountered in intracellular compartments, allowing the payload to be released or processed into an active form. The trigger must be sufficiently stable under circulation conditions while remaining responsive in the intended intracellular environment.

Common cleavable linker mechanisms include:

Protease-sensitive linkers: Peptide sequences such as Val-Cit or Val-Ala can be designed for enzymatic processing by lysosomal proteases. These structures are frequently studied when researchers want payload release to be associated with intracellular proteolytic activity. The cleavage sequence, neighboring structures, and payload-release mechanism all influence the final behavior.

Acid-sensitive linkers: Acid-labile structures, including hydrazone-based linkages, are designed to respond to lower-pH environments. Researchers need to evaluate whether the structure remains sufficiently stable under physiological conditions and whether cleavage occurs at the intended rate in acidic compartments.

Reduction-sensitive linkers: Disulfide-containing structures can respond to reducing conditions. Differences in thiol and glutathione levels between extracellular and intracellular environments provide a basis for investigating this release strategy. However, premature cleavage and the reactivity of the disulfide structure must be considered during stability evaluation.

Enzyme-responsive glycoside linkers: Certain structures use enzyme-sensitive glycosidic bonds, such as glucuronide-based motifs. Their performance depends on enzyme accessibility, linker architecture, and the ability of the cleavage process to generate the intended payload-containing product.

These mechanisms are not interchangeable. A protease-sensitive peptide linker, for example, requires a different biological processing pathway from a disulfide-based linker. Researchers should select the trigger according to the intracellular environment and the intended release profile.

How Do Non-Cleavable Linkers Work in ADC Development?

Non-cleavable linkers are designed to remain intact rather than releasing the payload through a dedicated chemical or enzymatic trigger. After the ADC is internalized, the antibody is degraded through intracellular proteolytic processes, mainly in lysosomal compartments. This processing generates a payload-containing catabolite that may still include part of the linker and an amino acid residue from the antibody.

This difference has an important structural consequence: the payload must retain suitable activity in the form of the resulting catabolite. Researchers therefore need to evaluate not only the original free payload but also the chemical structure and biological properties of the expected linker-payload-amino acid metabolite.

Non-cleavable designs are often investigated when linker stability is a major priority and the target-antibody combination supports effective internalization and lysosomal processing. However, their suitability depends on the payload's tolerance for the residual linker-containing structure and the ability of the ADC to reach the relevant intracellular compartment.

For this reason, non-cleavable linker selection should include catabolite characterization, intracellular processing studies, and payload activity evaluation. High chemical stability alone does not establish that a non-cleavable linker is suitable for a particular ADC candidate.

Cleavable vs Non-Cleavable Linkers: Key Structural Differences

The following comparison summarizes the main design considerations for researchers evaluating both linker types.

Evaluation Factor	Cleavable Linker	Non-Cleavable Linker
Release mechanism	Chemical or enzymatic cleavage	Intracellular antibody degradation
Structural feature	Contains a responsive cleavage site or bond	Uses a stable covalent connection without a dedicated release trigger
Typical mechanisms	Protease-sensitive peptide, acid-labile bond, disulfide, glucuronide	Stable thioether or other non-cleavable connections
Payload form after processing	May release the free payload or a designed payload-containing product	Often remains attached to linker and an antibody-derived amino acid residue
Important research focus	Trigger selectivity, cleavage kinetics, and premature release	Lysosomal processing and catabolite activity
Main design challenge	Balancing circulation stability and controlled cleavage	Ensuring the processed payload-containing catabolite remains active

This comparison is a starting point rather than a universal performance ranking. Actual ADC behavior is influenced by the antibody, conjugation site, drug-to-antibody ratio (DAR), payload chemistry, linker structure, and intracellular trafficking pathway.

When Should Researchers Consider a Cleavable Linker?

A cleavable linker is worth evaluating when the research design depends on a defined intracellular release mechanism. For example, a protease-sensitive linker may be considered when lysosomal enzyme processing is part of the intended release pathway. A disulfide-containing linker may be investigated when intracellular reducing conditions are relevant to the design.

Before selecting a cleavable linker, researchers should examine several questions:

• Does the target antibody undergo sufficient internalization?
• Does the ADC reach the intracellular compartment where the cleavage trigger is expected to function?
• Is the selected enzyme, pH condition, or reducing environment relevant to the intended release mechanism?
• Can the linker remain stable during synthesis, purification, storage, and circulation-related testing?
• Does cleavage generate the intended payload form, and is any additional self-immolative step required?
• Can the cleavage rate be measured and compared under relevant experimental conditions?

One point is particularly important: cleavage of the linker does not always mean that the free payload is immediately released. Some designs require a self-immolative spacer, such as a PABC-based unit, to complete payload liberation after the initial trigger is processed. Researchers should assess the entire release sequence rather than focusing only on the cleavage bond.

For projects exploring different conjugation structures, SINOPEG provides an ADC Linker product category for researchers to review relevant linker materials and structural options.

When Is a Non-Cleavable Linker Worth Investigating?

A non-cleavable linker may be a suitable research direction when the design prioritizes a stable antibody-payload connection and relies on intracellular antibody degradation to produce the active catabolite. This approach is especially relevant when the payload can retain activity while attached to the linker and an antibody-derived amino acid residue.

Researchers should pay close attention to:

• Antibody internalization: The ADC needs to enter the target cell and reach compartments where antibody degradation can occur.
• Lysosomal processing: The antibody must be processed sufficiently to generate the expected payload-containing catabolite.
• Catabolite activity: The residual linker and amino acid structure must not prevent the payload from exerting its intended biological activity.
• Intracellular distribution: The charge, polarity, and membrane permeability of the catabolite may influence its intracellular behavior.
• Conjugate stability: The linker should maintain the required chemical integrity throughout the relevant development and testing stages.

Researchers should not assume that non-cleavable linkers always produce better stability or better overall ADC performance. A highly stable linker may still be unsuitable if the antibody is not efficiently internalized or if the resulting catabolite has insufficient activity.

For designs that involve thiol-based conjugation, it is useful to review the available Maleimide-functionalized PEG products. Maleimide groups can react with thiol groups under suitable conditions, but the final conjugate's stability depends on the complete molecular structure and reaction conditions. The presence of a maleimide group alone does not determine whether an ADC linker is cleavable or non-cleavable.

How Does PEG Affect Cleavable and Non-Cleavable ADC Linker Design?

PEG, or polyethylene glycol, is commonly considered as a hydrophilic spacer or structural component in bioconjugation research. In ADC linker design, PEG segments can influence molecular spacing, flexibility, and the overall hydrophilic-lipophilic balance of a drug-linker structure.

However, PEG and the cleavage mechanism perform different roles. A PEG segment does not automatically make a linker cleavable. If the ADC is designed for enzyme-triggered release, the enzyme-sensitive sequence remains the functional cleavage element. If the design is non-cleavable, the PEG segment may form part of a stable spacer without introducing a dedicated payload-release trigger.

PEG structure may be evaluated in both linker approaches for several reasons:

• Hydrophilicity: PEG may help address solubility and aggregation challenges associated with hydrophobic payloads, although the effect depends on the complete conjugate.
• Spatial separation: A PEG spacer can alter the distance between the antibody and payload, potentially influencing steric accessibility and molecular interactions.
• Flexibility: PEG chain length and architecture can affect the conformational freedom of the linker-payload region.
• Structural consistency: Defined PEG chain lengths can make it easier to compare linker variants in controlled research studies.

These effects should be experimentally verified. Increasing PEG length does not automatically improve ADC solubility, stability, or biological activity. The antibody, payload hydrophobicity, conjugation site, DAR, and formulation all contribute to the final properties.

Researchers comparing defined PEG structures can explore SINOPEG's Heterobifunctional Monodisperse PEG category. Heterobifunctional PEGs contain two different terminal functional groups, allowing different coupling reactions to be considered at each end. Their suitability depends on the specific end groups and the intended molecular design.

Monodisperse PEG or Polydisperse PEG: Which Is More Suitable for ADC Research?

PEG chain distribution is another structural factor to consider. Monodisperse PEG materials have a defined number of repeating ethylene oxide units, while polydisperse PEG materials contain a distribution of chain lengths and molecular weights.

For linker structure-activity studies, monodisperse PEG can be useful when researchers want to compare materials with clearly defined chain lengths. It helps reduce uncertainty associated with PEG chain-length distribution and supports more controlled structural comparisons.

Polydisperse PEG may still be appropriate for certain research or formulation applications. The choice depends on the required structural definition, analytical strategy, and intended use. Monodispersity alone does not guarantee better ADC performance, but it can be valuable when precise molecular characterization is important.

For projects requiring defined PEG structures, researchers can review the broader SINOPEG PEG derivatives and functionalized PEG product range to identify materials relevant to their conjugation and linker development requirements.

What Should Be Evaluated Before Selecting an ADC Linker?

Rather than selecting a linker based on one structural feature, researchers should evaluate the full antibody-linker-payload system. The following factors provide a practical framework for early-stage linker screening.

Release mechanism and intracellular pathway: Define whether payload release should depend on protease activity, acidic conditions, reducing conditions, or lysosomal degradation of the antibody. The selected mechanism should match the expected intracellular processing pathway.

Circulation-related stability: Assess whether the linker remains intact under relevant plasma or serum conditions. For cleavable structures, premature cleavage is a major concern. For non-cleavable structures, the integrity of the covalent connection should also be monitored.

Conjugation chemistry: Confirm that the functional groups are compatible with the antibody attachment site and the payload-linker intermediate. Maleimide-thiol coupling, amine-reactive chemistry, and bioorthogonal reactions each have different reaction requirements and potential limitations.

Payload properties: Consider payload potency, hydrophobicity, solubility, and the structural requirements for biological activity. Non-cleavable designs require particular attention to the activity of the expected catabolite.

PEG architecture: If PEG is included, evaluate its chain length, dispersity, terminal functional groups, and position within the linker. The spacer should be considered as part of the complete molecular architecture, not as an isolated performance solution.

Conjugate heterogeneity and DAR: Evaluate how the conjugation strategy affects drug loading and product distribution. DAR is not determined by PEG chain length alone. It is influenced by the antibody attachment sites, reaction design, and conjugation conditions.

Analytical characterization: Select suitable methods to confirm identity, purity, molecular weight, conjugation, aggregation, and stability. Depending on the structure and research stage, methods may include LC-MS, HPLC, SEC-HPLC, HIC, NMR, UV-Vis, and relevant biological assays.

A Practical Workflow for Comparing Cleavable and Non-Cleavable Linkers

A controlled comparison can help researchers avoid choosing a linker based on assumptions. A practical early-stage workflow may include the following steps:

1. Define the intended release pathway. Identify whether the design requires a specific cleavage trigger or relies on lysosomal antibody degradation.
2. Choose candidate linker structures. Select representative cleavable and/or non-cleavable structures that are compatible with the antibody and payload.
3. Confirm conjugation compatibility. Check reactive groups, coupling conditions, and potential side reactions before preparing ADC candidates.
4. Measure chemical stability. Compare linker integrity under relevant buffer, serum, storage, and processing conditions.
5. Characterize release or catabolite formation. For cleavable linkers, assess cleavage kinetics and released products. For non-cleavable linkers, identify the resulting catabolites after antibody degradation.
6. Evaluate the complete conjugate. Assess DAR distribution, aggregation, binding, internalization, and relevant cell-based activity.
7. Compare results under consistent conditions. Keep the antibody, payload, conjugation site, and analytical methods as consistent as possible when comparing linker variants.

This workflow helps distinguish the effect of linker chemistry from the influence of other ADC components. It also provides a more reliable basis for deciding whether a cleavable or non-cleavable design should move forward to further optimization.

How SINOPEG Supports PEG-Based Linker and ADC Research

SINOPEG focuses on PEG derivatives, monodisperse PEG materials, functionalized PEGs, and related specialty materials for research and development applications. For ADC linker projects, material selection may involve more than identifying a PEG chain length. Researchers also need to consider terminal functional groups, molecular architecture, reaction compatibility, and the intended role of each component in the final conjugate.

Depending on the project requirements, relevant material categories may include ADC linker materials, heterobifunctional monodisperse PEG, and functionalized PEG derivatives. These categories provide starting points for reviewing structural options and identifying materials for further technical evaluation.

For example, mPEG7-SC is an NHS-carbonate-functionalized PEG derivative. Its reactive carbonate group can react with primary amines to form a carbamate linkage under suitable conditions. It can be considered as an example of a defined PEG reactive building block, but it should not be treated as a complete bifunctional ADC linker by itself.

When evaluating materials for ADC research, researchers should confirm the product's molecular structure, functional group identity, specifications, storage requirements, and compatibility with the planned reaction. The final choice should be based on the intended conjugate design and experimental validation.

For more information about PEG-based materials and linker-related options, visit SINOPEG or contact the technical team with the required molecular structure, functional groups, and research application.

Frequently Asked Questions About Cleavable and Non-Cleavable ADC Linkers

What is the main difference between cleavable and non-cleavable ADC linkers?

Cleavable linkers contain a chemical or enzymatic trigger that enables payload release under specific conditions. Non-cleavable linkers remain attached until the antibody is degraded inside the cell, producing a payload-containing catabolite.

Which is more stable, a cleavable or non-cleavable ADC linker?

Non-cleavable linkers are generally designed to resist cleavage and remain intact during intracellular processing until antibody degradation. Cleavable linkers are designed to respond to a specific trigger, so their stability must be evaluated against both circulation conditions and the intended release environment. Actual stability depends on the complete linker structure.

Are Val-Cit linkers cleavable or non-cleavable?

Val-Cit is a protease-sensitive peptide sequence commonly used in cleavable ADC linker designs. It is intended to undergo enzymatic processing under suitable intracellular conditions. Some structures also include a self-immolative spacer to facilitate payload release after peptide cleavage.

Does PEG make an ADC linker cleavable?

No. PEG is commonly used as a hydrophilic spacer or structural component. Whether an ADC linker is cleavable depends on the presence and function of its release mechanism, such as a protease-sensitive peptide, acid-labile bond, or disulfide bond.

Why use monodisperse PEG in ADC linker research?

Monodisperse PEG has a defined number of repeating units, which can help researchers compare linker structures with more consistent chain lengths. It is useful for controlled structural studies, although monodispersity alone does not guarantee improved ADC performance.

Can maleimide-functionalized PEG be used in ADC development?

Maleimide-functionalized PEG can be considered for thiol-based conjugation because maleimide groups react with suitable thiol groups. Its application depends on the complete molecular structure, reaction conditions, and required conjugate stability. A maleimide group does not by itself define the payload-release mechanism.

How should researchers compare cleavable and non-cleavable linkers?

Researchers should compare linker stability, release or catabolite formation, conjugation compatibility, DAR distribution, aggregation, antibody binding, internalization, and relevant biological activity. Comparisons are more meaningful when other ADC components and testing conditions are controlled.

Scientific References

McCombs JR, Owen SC. Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry. AAPS Journal. 2015;17(2):339–351. DOI: 10.1208/s12248-014-9710-8.

Udofa E, Sankholkar D, Mitragotri S, Zhao Z. Antibody drug conjugates in the clinic. Bioengineering & Translational Medicine. 2024;9(6):e10677. DOI: 10.1002/btm2.10677.

Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Frontiers in Pharmacology. 2018.

Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein & Cell. 2018;9(1):33–46.

Note: These references discuss general ADC linker mechanisms and design considerations. They do not constitute experimental validation or clinical performance evidence for any specific SINOPEG product.